H295R: Difference between revisions
Content deleted Content added
Adding relevant categories. |
No edit summary |
||
| Line 1: | Line 1: | ||
<!--- Don't mess with this line! --->{{New unreviewed article|date=May 2015}} |
|||
<!--- Write your article below this line ---> |
|||
'''H295R''' (also referred to as NCI-H295R) is an [[Angiotensin|angiotensin-II]]-responsive [[steroid]]-producing [[Adrenal cortex|adrenocortical]] [[cell line]].<ref name="TP-150519-001">{{cite journal |author= Wang T, Rainey WE |title= Human Adrenocortical Carcinoma Cell Lines. |journal= Mol. Cell. Endocrinol. |volume= 351 |issue= 1 |pages= 58–65 |year= 2012 |pmid= 21924324 |doi= 10.1016/j.mce.2011.08.041 |url= http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288152/#R30 }}</ref> It was initially isolated in 1980 from a 48-year-old female patient diagnosed with [[adrenocortical carcinoma]].<ref name="TP-150519-001" /><ref name="TP-150519-002">{{cite journal |author= Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV |title= Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. |journal= Cancer Res. |volume= 50 |issue= 17 |pages= 5488–5496 |year= 1990 |pmid= 2386954 |doi= |url= http://cancerres.aacrjournals.org/content/50/17/5488.long }}</ref> The initial polyclonal populations of tumor cells obtained from the patients' tumor were cultured and the resultant cell line was called NCI-H295.<ref name="TP-150519-001" /><ref name="TP-150519-002" /> Because of slow growth rates and easy detachment of the original NCI-H295 strains, efforts were made to select a population of cells with better monolayer attachment and more rapid growth.<ref name="TP-150519-001" /> Three strains were developed, based on the serum supplement used for growth, which have been termed H295R-S1, H295R-S2 and H295R-S3.<ref name="TP-150519-001" /><ref name="TP-150519-003">{{cite journal |author= Rainey WE, Saner K, Schimmer BP |title= Adrenocortical cell lines. |journal= Mol. Cell. Endocrinol. |volume= 228 |issue= 1-2 |pages= 23–38 |year= 2004 |pmid= 15541570 |doi= 10.1016/j.mce.2003.12.020 |url= }}</ref> All three strains grow as adherent monolayer cultures.<ref name="TP-150519-001" /> |
'''H295R''' (also referred to as NCI-H295R) is an [[Angiotensin|angiotensin-II]]-responsive [[steroid]]-producing [[Adrenal cortex|adrenocortical]] [[cell line]].<ref name="TP-150519-001">{{cite journal |author= Wang T, Rainey WE |title= Human Adrenocortical Carcinoma Cell Lines. |journal= Mol. Cell. Endocrinol. |volume= 351 |issue= 1 |pages= 58–65 |year= 2012 |pmid= 21924324 |doi= 10.1016/j.mce.2011.08.041 |url= http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288152/#R30 }}</ref> It was initially isolated in 1980 from a 48-year-old female patient diagnosed with [[adrenocortical carcinoma]].<ref name="TP-150519-001" /><ref name="TP-150519-002">{{cite journal |author= Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV |title= Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. |journal= Cancer Res. |volume= 50 |issue= 17 |pages= 5488–5496 |year= 1990 |pmid= 2386954 |doi= |url= http://cancerres.aacrjournals.org/content/50/17/5488.long }}</ref> The initial polyclonal populations of tumor cells obtained from the patients' tumor were cultured and the resultant cell line was called NCI-H295.<ref name="TP-150519-001" /><ref name="TP-150519-002" /> Because of slow growth rates and easy detachment of the original NCI-H295 strains, efforts were made to select a population of cells with better monolayer attachment and more rapid growth.<ref name="TP-150519-001" /> Three strains were developed, based on the serum supplement used for growth, which have been termed H295R-S1, H295R-S2 and H295R-S3.<ref name="TP-150519-001" /><ref name="TP-150519-003">{{cite journal |author= Rainey WE, Saner K, Schimmer BP |title= Adrenocortical cell lines. |journal= Mol. Cell. Endocrinol. |volume= 228 |issue= 1-2 |pages= 23–38 |year= 2004 |pmid= 15541570 |doi= 10.1016/j.mce.2003.12.020 |url= }}</ref> All three strains grow as adherent monolayer cultures.<ref name="TP-150519-001" /> |
||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
<!--- After listing your sources please cite them using inline citations and place them after the information they cite. Please see http://en.wikipedia.org/wiki/Wikipedia:REFB for instructions on how to add citations. ---> |
|||
* |
|||
* |
|||
* |
|||
* |
|||
<!--- STOP! Be warned that by using this process instead of Articles for Creation, this article is subject to scrutiny. As an article in "mainspace", it will be DELETED if there are problems, not just declined. If you wish to use AfC, please return to the Wizard and continue from there. ---> |
|||
[[Category:Steroid hormones]] |
[[Category:Steroid hormones]] |
||
[[Category:Cell lines]] |
[[Category:Cell lines]] |
||
Revision as of 21:43, 13 June 2015
H295R (also referred to as NCI-H295R) is an angiotensin-II-responsive steroid-producing adrenocortical cell line.[1] It was initially isolated in 1980 from a 48-year-old female patient diagnosed with adrenocortical carcinoma.[1][2] The initial polyclonal populations of tumor cells obtained from the patients' tumor were cultured and the resultant cell line was called NCI-H295.[1][2] Because of slow growth rates and easy detachment of the original NCI-H295 strains, efforts were made to select a population of cells with better monolayer attachment and more rapid growth.[1] Three strains were developed, based on the serum supplement used for growth, which have been termed H295R-S1, H295R-S2 and H295R-S3.[1][3] All three strains grow as adherent monolayer cultures.[1]
References
- ^ a b c d e f Wang T, Rainey WE (2012). "Human Adrenocortical Carcinoma Cell Lines". Mol. Cell. Endocrinol. 351 (1): 58–65. doi:10.1016/j.mce.2011.08.041. PMID 21924324.
- ^ a b Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV (1990). "Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis". Cancer Res. 50 (17): 5488–5496. PMID 2386954.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Rainey WE, Saner K, Schimmer BP (2004). "Adrenocortical cell lines". Mol. Cell. Endocrinol. 228 (1–2): 23–38. doi:10.1016/j.mce.2003.12.020. PMID 15541570.
{{cite journal}}: CS1 maint: multiple names: authors list (link)